MediPharm Labs Still Hits C$8.5M Despite Sequential Drop, More On That In Q3 2023 Financial Report
MediPharm Labs Still Hits C$8.5M Despite Sequential Drop, More On That In Q3 2023 Financial Report
MediPharm Labs Corp. (TSX:LABS) (OTCQB:MEDIF) (FSE: MLZ) reported its financial results for the three months ended September 30, 2023, with a revenue of C$8.5 million. This reflects a decrease of around C$1 million sequentially but an increase of C$1.3 million over the year.
Medipharm Labs Co 多倫多證券交易所股票代碼：LABS）（OTCQB: MEDIF）（FSE：MLZ）公佈了截至2023年9月30日的三個月的財務業績，其中包括 收入爲850萬加元。這反映出連續減少約100萬加元，但同比增加了130萬加元。
CEO David Pidduck emphasized the company's focus on margins, cost reductions and profitability, noting the strong balance sheet and improved profitability for strategic investments in revenue growth.
首席執行官 大衛皮德杜克 強調了公司對利潤率、成本降低和盈利能力的關注，並指出收入增長方面的戰略投資資產負債表強勁，盈利能力有所提高。
Q3 2023 Financial Highlights
2023 年第三季度財務亮點
- Gross profit of C$2.4M or 28%, positive for the fourth consecutive quarter and the highest since Q4 2019.
- Adjusted EBITDA improved to negative C$2.4M, a 53% improvement over the prior year and from negative C$3.2M in Q2 2023, driven by margin expansion initiatives and cost reductions.
- Successful integration of VIVO resulted in approximately C$7M in annualized savings, with an additional restructuring in Q3 contributing about C$3M in annualized savings from Q4 2023.
- A strong balance sheet with C$13M in cash and less than C$3 million in debt as of September 30, 2023, reflects a current cash position of approximately C$19M.
- 毛利 爲240萬加元，佔28％，連續第四個季度爲正數，爲2019年第四季度以來的最高水平。
- 調整後 EBITDA 在利潤率擴張計劃和成本降低的推動下，增至負240萬加元，比上年增長53％，從2023年第二季度的負320萬加元。
- VIVO的成功整合帶來了約700萬加元的年化儲蓄，第三季度的額外重組從2023年第四季度起每年可節省約300萬加元。
- 一個強大的 資產負債表 截至2023年9月30日，其現金爲1300萬加元，債務不到300萬加元，反映出目前的現金狀況約爲1900萬加元。
Additionally, the company settled a 'long-lasting' commercial agreement dispute receiving a total of C$9M. This includes net cash of C$7.3M collected in October, C$1M in Tilray Brands, Inc. (NASDAQ:TLRY) cannabis products, and a four-year agreement where Tilray will purchase C$0.5M of MediPharm products.
此外，該公司解決了一起 “長期” 的商業協議糾紛，總金額爲900萬加元。這包括10月份收取的730萬加元的淨現金，100萬加元的淨現金 Tilray Brands, Inc. 納斯達克股票代碼：TLRY）的大麻產品，以及一項爲期四年的協議，根據該協議，蒂爾雷將購買50萬加元的MediPharm產品。
Greg Hunter, CFO of MediPharm, highlighted continued progress in Q3, emphasizing improvements in gross margins, expense reduction, and reduced cash burn toward profitability.
格雷格亨特，MediPharm首席財務官強調了第三季度的持續進展，強調了毛利率的提高、開支的減少以及盈利方面的現金消耗減少。
Price Action
價格走勢
MEDIF's shares were trading 2.23% down at $0.0503 per share on Tuesday afternoon.
週二下午，MEDIF的股價下跌2.23％，至每股0.0503美元。
Related News:
相關新聞：
- New CBD & THC Cannabis Oils Now Shipping To Australia From Canada
- MediPharm Labs Breaks Free From Royalty Agreement, What It Means & What's Next
- 新的CBD和THC大麻油現已從加拿大運往澳大利亞
- MediPharm Labs 打破了特許權使用費協議、這意味着什麼以及下一步會發生什麼
Image by PiggyBank On Unsplash
圖片由 PiggyBank On Unsplash
譯文內容由第三人軟體翻譯。